ClinicalTrials.gg
RecruitingNCT06943521Updated Dec 11, 2025

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

A Phase 1/2 interventional study of MT-4561 in Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC) and Esophageal Cancer, sponsored by Tanabe Pharma America, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
644th of 993
27 · median 41
Started
2025
with 60 others
Phase 1/2
157 of 1,099
42 open now
Primary completion
2028-08
later than 253 of 346 live
Registered
1,013th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 644th largest by planned enrollment of the 993 interventional ones that give a count, is one of 61 that started in 2025, is one of 157 in phase 1/2, reaches primary completion later than 253 of the 346 other live ones, and was the 1,013th registered.

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 574 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts.

Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design.

The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Esophageal Cancer
  • Gastric Cancer
  • Biliary Tract Cancer
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Prostate Cancer
  • Urothelial Carcinoma
  • Neuroendocrine Tumor (NET)
  • Neuroendocrine Carcinoma (NEC)
  • Soft Tissue Sarcoma
  • Nuclear Protein in Testis (NUT) Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable to or refuse further standard therapies will be enrolled.

  • Male or female patient aged 18 years or older at the time of signing the form
  • ≥ 1 by the v1.1
  • (ECOG) performance status: 0 to 1
  • of at least 3 months
  • Adequate bone marrow function
  • Adequate hepatic function
  • Adequate renal function estimated ≥ 60 mL/min calculated using the Cockcroft and Gault equation or by institutional method
  • Part 1: Patients must have a confirmed histologic or cytologic diagnosis of one of the following solid tumors for participation in the study: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer, gastric cancer, biliary tract cancer, pancreatic ductal adenocarcinoma (PDAC), breast cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, urothelial carcinoma, neuroendocrine tumor (NET) or neuroendocrine carcinoma (NEC), soft tissue sarcoma, and NUT carcinoma.

Main Exclusion Criteria:

  • Patients with active brain or
  • Any unresolved toxicity ≥ Grade 2 from previous anticancer therapy except for alopecia
  • Prior systemic anticancer therapy within 4 weeks before first dose of medicinal product (IMP) or 5 half-lives, whichever is shorter, and prior radiotherapy within 2 weeks before first dose of IMP
  • History of congenital long syndrome or ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes)
  • Patients who received drugs with a known risk of QT interval prolongation or Torsades de pointes within 14 days or 5 half-lives, whichever is shorter, before the start of IMP administration
  • QT interval corrected for heart rate using Fridericia's correction (QTcF) > 470 msec at screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Part 1 (Dose-escalation)

    Intravenous (IV) infusion of MT-4561 once every week in 28-day cycle, until disease progression or discontinuation criteria are met.

    Drug: MT-4561

Interventions

  • DrugMT-4561

    i.v.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Event, Dose limiting toxicities (DLTs)

    Part 1 Frequency, duration, and severity (Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) of adverse events, dose limiting toxicity (DLT), physical examinations, changes in clinical laboratory values (e.g., hematology, chemistry, and urinalysis), vital signs (e.g., heart rate, blood pressure, respiratory rate), electrocardiogram DLTs are defined as any event meeting the DLT criteria at least possibly related to MT-4561 for Cycle 1 (i.e., DLT monitoring window is approximately 28 days). Events with a clear alternative explanation will not be considered DLTs.

    Time frame: a 28-day cycle

  2. Number of Patients with Adverse events (AEs)

    Part 1 Frequency, duration, and severity (Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) of adverse events, dose limiting toxicity (DLT), physical examinations, changes in clinical laboratory values (e.g., hematology, chemistry, and urinalysis), vital signs (e.g., heart rate, blood pressure, respiratory rate), electrocardiogram Adverse event: An AE is defined as any untoward medical occurrence in a clinical study patient administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of an IMP, whether it is considered related to the IMP.

    Time frame: Screening through 30 days after last dose

Secondary outcomes

  1. Cmax of MT-4561

    To determine the pharmacokinetics(PK) profile of MT-4561

    Time frame: Cycle 1 Day 1 through Cycle 2 Day 22 (each cycle is 28 days)

  2. time corresponding to occurrence of Cmax (tmax)

    To determine the pharmacokinetics(PK) profile of MT-4561

    Time frame: Cycle 1 Day 1 through Cycle 2 Day 22 (each cycle is 28 days)

  3. minimum observed plasma concentration (Cmin)

    To determine the pharmacokinetics(PK) profile of MT-4561

    Time frame: Cycle 1 Day 1 through Cycle 2 Day 22 (each cycle is 28 days)

  4. area under the concentration-time curve from zero up to 168 hours post-dose (AUC0-168)

    To determine the pharmacokinetics(PK) profile of MT-4561

    Time frame: Cycle 1 Day 1 through Cycle 2 Day 22 (each cycle is 28 days)

  5. Renal clearance (CL) after the first dose and at steady state

    To determine the pharmacokinetics(PK) profile of MT-4561

    Time frame: Cycle 1 Day 1 through Cycle 2 Day 22 (each cycle is 28 days)

  6. dose proportionality

    To determine the pharmacokinetics(PK) profile of MT-4561

    Time frame: Cycle 1 Day 1 through Cycle 2 Day 22 (each cycle is 28 days)

  7. accumulation ratio

    To determine the pharmacokinetics(PK) profile of MT-4561

    Time frame: Cycle 1 Day 1 through Cycle 2 Day 22 (each cycle is 28 days)

  8. Objective Response Rate (ORR)

    ORR defined as the proportion of patients with a best overall response of complete response (CR) and partial response (PR) recorded from start of study intervention until the last objective response documented.

    Time frame: From Cycle 1 Day 1 until Progressive Disease/Death/or start of new anticancer therapy, up to approximately 3 years

  9. Disease control rate (DCR)

    DCR defined as the proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD).

    Time frame: From Cycle 1 Day 1 until Progressive Disease/Death/or start of new anticancer therapy, up to approximately 3 years

  10. Clinical benefit rate (CBR)

    CBR defined as the proportion of patients with best overall response of complete response (CR), partial response (PR), or who have had stable disease (SD) for a minimum of 6 months after the first dose of study intervention.

    Time frame: From Cycle 1 Day 1 until Progressive Disease/Death/or start of new anticancer therapy, up to approximately 3 years

  11. Best overall response (BoR)

    BoR defined as the best response in the order of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) among all overall responses recorded from the start of the study intervention until the last objective response recorded.

    Time frame: From Cycle 1 Day 1 until Progressive Disease/Death/or start of new anticancer therapy, up to approximately 3 years

  12. Duration of Response (DoR)

    Investigator Review according to RECIST v1.1 criteria

    Time frame: From Cycle 1 Day 1 until Progressive Disease/Death/or start of new anticancer therapy, up to approximately 3 years

  13. Progression-Free Survival (PFS)

    Investigator Review according to RECIST v1.1 criteria

    Time frame: From Cycle 1 Day 1 until the first documented objective disease progression or death due to any cause, whichever occurs first, up to approximately 3 years

  14. Overall Survival (OS)

    Investigator Review according to RECIST v1.1 criteria

    Time frame: From Cycle 1 Day 1 until Death, up to approximately 3 years

  15. Duration of stable disease (SD)

    Time from the date of the first dose of the study intervention to the first documented progressive disease (PD).

    Time frame: From Cycle 1 Day 1 until Progressive Disease/Death/or start of new anticancer therapy, up to approximately 3 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2028, 40 months after the start.

Of 93 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 40 months is below that.

Counting every sponsor, half of 138 studies reached it within 61 months; a quarter within 47 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 24, 2025
StartActual
Apr 18, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943521
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Apr 18, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Dec 11, 2025

Study contacts

Clinical Trials Information Desk, to prevent miscommunication,
Contact
information.US@mb.tanabe-pharma.com
Please E-mail
Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion